Bausch + Lomb launches Arise orthokeratology lens fitting system in Europe, UK and US

News
Article

The Arise system utilises advanced algorithms to interpret corneal topography images, recommending lenses without requiring a fitting set

A woman stands at a mirror, inserting a contact lens. Image credit: ©Camerene Pendl/peopleimages.com – stock.adobe.com

The orthokeratology lenses are indicated for the temporary reduction of myopia up to 5.00 diopters with eyes having astigmatism up to 1.50 diopters. Image credit: ©Camerene Pendl/peopleimages.com – stock.adobe.com

Bausch + Lomb announced the launch of Arise, a lens fitting system that uses intelligent, cloud-based technology to aid in the orthokeratology lens design process, in Europe, the United Kingdom and the United States. According to a press release, Arise is capable of syncing directly with topographers to create precise lens designs for the treatment of myopia in the matter of seconds. The system also utilises the first orthokeratology lens design with toric peripheral curves approved by the US Food and Drug Administration to treat myopia overnight, Bausch + Lomb noted in the release.

“Traditional orthokeratology lens fitting methods can be complex and time-consuming,” said Yang Yang, president of Global Vision Care at Bausch + Lomb. “The Arise platform’s streamlined fitting process will reduce chair time and increase efficiency for eye care professionals.”

Arise works through advanced algorithms which interpret corneal topography images and recommends lens designs without a fitting set required. The system evaluates lens centration and patient progress by using an overnight outcome map library and recommends any adjustments needed following overnight wear. Arise uses a cloud-based platform, which also allows secure access to patient data and provides direct support from the Bausch + Lomb expert consultation team. The system is designed for lens fitters of all experience levels.

“Arise combines all aspects of the orthokeratology process—from topography capture to lens design and more—into one seamless, user-friendly technology,” said Brooke Messer, OD, FAAO, FSLS, of Vance Thompson Vision in West Fargo, North Dakota, in the release. “The ease and precision of Arise will be a welcome addition to my practice.”

Arise is now commercially available in the US, the UK, and Europe.

The Boston orthokeratology (oprifocon A) shaping lenses for overnight wear available with Arise are indicated for use in reduction of myopic refractive error in non-diseased eyes. The lenses can be used in part of the Bausch + Lomb Vision Shaping Treatment VST process for the temporary reduction of myopia up to 5.00 diopters with eyes having astigmatism up to 1.50 diopters.

Reference:

  1. Bausch + Lomb launches Arise orthokeratology lens system in the United States. News release. Bausch + Lomb. March 17, 2025. Accessed March 17, 2025.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.